



Clinical trial results: Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI)

Summary

EudraCT number	2015-005346-58
Trial protocol	DE CZ ES
Global end of trial date	31 December 2020

Results information

Result version number	v2 (current)
This version publication date	19 August 2023
First version publication date	06 November 2022
Version creation reason	<ul style="list-style-type: none">New data added to full data set add publication link

Trial information

Trial identification

Sponsor protocol code	RIMINI
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04114188
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Charité - University Hospital of Berlin
Sponsor organisation address	Charitéplatz 1, Berlin, Germany, 10117
Public contact	Prof. Dr. Petra Reinke, Charité - Universitätsmedizin Berlin, +49 030 450 653490, petra.reinke@charite.de
Scientific contact	Prof. Dr. Petra Reinke, Charité - Universitätsmedizin Berlin, +49 030 450 653490, petra.reinke@charite.de

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 March 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 December 2020
Global end of trial reached?	Yes
Global end of trial date	31 December 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

CMV, EBV, BKV PCR monitoring according to protocol will be performed routinely in each center. All patients will receive 100 days valganciclovir prophylaxis at doses adjusted according eGFR and Cotrimoxazol (trimethoprim / sulfamethoxazole) 480mg/day for 6 months.

Protection of trial subjects:

Trial was conducted according to the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 December 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 5
Country: Number of subjects enrolled	Czechia: 34
Country: Number of subjects enrolled	Germany: 29
Worldwide total number of subjects	68
EEA total number of subjects	68

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	65
From 65 to 84 years	3

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details:

Date of study / recruitment start December 1st, 2016

Date of termination of recruitment December 31, 2020

Recruitment at 3 study centers.

Pre-assignment

Screening details:

PRE-TREATMENT VISIT (SCREENING VISIT/ASSESSMENT at POD 0, inclusion/exclusion criteria will be verified, written informed consent will be obtained, baseline examination and several immune monitoring platforms will be assessed

1098 Subjects assessed for eligibility

1029 Subjects excluded

69 Subjects were allocated

2 no intervention

Period 1

Period 1 title	Treatment (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Tacrolimus Group
------------------	------------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	INFLIXIMAB
Investigational medicinal product code	
Other name	SUB02681MIG
Pharmaceutical forms	Powder for concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

5mg/kg b.w. – once daily on day 2

Intravenous infusion

Investigational medicinal product name	Thymoglobulin
Investigational medicinal product code	
Other name	ANTITHYMOCYTE IMMUNOGLOBULIN, SUB128808
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1.5mg/kg b.w. – once daily on day0 and on day1

intravenous infusion

Investigational medicinal product name	TACROLIMUS
Investigational medicinal product code	
Other name	SUB10797MIG
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

before surgery 0,1 mg/kg and 0.2mg/kg after surgery

10-15 ng/mL, POD1-POD13

5-8 ng/mL POD 14-90

4-6 ng/mL POD >90

Tacrolimus is recommended as routine post-transplant immunosuppression. Tacrolimus doses will be modified according to trough levels as recommended by manufacturer.

Investigational medicinal product name	Prednisolone
Investigational medicinal product code	
Other name	SUB10018MIG
Pharmaceutical forms	Suspension for injection
Routes of administration	Intravenous use, Oral use

Dosage and administration details:

500 mg - once daily on day0 and on day1 as intravenous infusion From day 2 oral administration, dose will be slowly tapered down to 5 mg at the POD 7

Number of subjects in period 1	Tacrolimus Group
Started	68
Completed	68

Baseline characteristics

Reporting groups

Reporting group title	Treatment
-----------------------	-----------

Reporting group description: -

Reporting group values	Treatment	Total	
Number of subjects	68	68	
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	49.6		
standard deviation	± 10.2	-	
Gender categorical			
Units: Subjects			
Female	12	12	
Male	56	56	
Race			
Units: Subjects			
Caucassian	68	68	

End points

End points reporting groups

Reporting group title	Tacrolimus Group
Reporting group description: -	

Primary: efficacy failure of the induction regimen

End point title	efficacy failure of the induction regimen ^[1]
End point description: acute rejection, graft loss or poor graft function defined as eGFR<40 ml/min. In total, 22 out of 67 KTRs (32.84%) have experienced efficacy failure during the 12 months study follow-up, the upper-bound of the exact one-sided 95% confidence interval is 43.47%. This result fulfills the predefined criteria of efficacy failure rate of no more than 40% with an upper-bound of the exact one-sided 95% confidence interval of no more than 50%.	
End point type	Primary
End point timeframe: 12 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: see publication: Primary endpoint occurred in 22 of 67 patients (32.84%), with upper bound of an exact 1-sided 95% CI of 43.47%, which met the predefined criteria (efficacy failure of <40% and upper-bound 95% CI of <50%) and was similar in the historical matched cohort. By 12 mo, 79.1% of patients remained on the study protocol. Lower rates of BK replication (6% versus 22.4%; P = 0.013) but higher rates of de novo DSAs (11.9% versus 1.5%; P = 0.039) were observed in the study cohort.

End point values	Tacrolimus Group			
Subject group type	Reporting group			
Number of subjects analysed	67			
Units: Subjects				
graft loss	4			
acute rejection	11			
persistent poor graft function	13			
acute rejection+poor graft function	5			
acute rejection+ graft failure	1			

Statistical analyses

No statistical analyses for this end point

Secondary: Discontinuation and Remain of study treatment by 12 months posttransplant

End point title	Discontinuation and Remain of study treatment by 12 months posttransplant
End point description:	
End point type	Secondary

End point timeframe:

12 months

End point values	Tacrolimus Group			
Subject group type	Reporting group			
Number of subjects analysed	67			
Units: Subjects				
remained on the study protocol	53			
permanent discontinuation	14			

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of acute and chronic lesions

End point title	Incidence of acute and chronic lesions
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

12 months posttransplant

End point values	Tacrolimus Group			
Subject group type	Reporting group			
Number of subjects analysed	67			
Units: Subjects				
chronic T-cell mediated rejection grade II	1			
chronic active antibody-mediated rejection	1			
poor graft function by antibody-mediated rejection	2			
acute rejection	11			

Statistical analyses

No statistical analyses for this end point

Secondary: protocolar biopsy

End point title	protocolar biopsy
-----------------	-------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

12 months

End point values	Tacrolimus Group			
Subject group type	Reporting group			
Number of subjects analysed	68			
Units: Subjects				
acute/chronic rejection lesions	5			
active antibody mediated rejection	2			
chronic active antibody mediated rejection	2			
acute T-cell mediated rejection IIA	1			
not performed due to graft failure	4			
patient refusal	4			
organization difficulties	12			
no kidney tissues	1			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

12 months

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20
--------------------	----

Reporting groups

Reporting group title	Tacrolimus Group
-----------------------	------------------

Reporting group description: -

Serious adverse events	Tacrolimus Group		
Total subjects affected by serious adverse events			
subjects affected / exposed	41 / 67 (61.19%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
lung carcinoma with metastasis sus			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
vasoproliferative retinal tumor			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
coronary 3 vessel heart disease			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
hypertensiv pulmonary edema			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

pulmonary embolism			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
relapsing dialysis shunt thrombosis			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombosis of lower artery of the graft kidney			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
thrombosis vena iliaca externa right			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ventricular fibrillation			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
aneurysmal shunt vein			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hemorrhagic			
subjects affected / exposed	2 / 67 (2.99%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
active humoral rejection			

subjects affected / exposed	3 / 67 (4.48%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 0		
proof of donor-specific antibodies HLA class II			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
delayed graft function			
subjects affected / exposed	5 / 67 (7.46%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
graft non-function			
subjects affected / exposed	5 / 67 (7.46%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
Hernia umbilicalis incarcerata			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
nephrectomy bleeding cyst kidney right side			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hemorrhage after biopsy			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Right testide hematoma- surgical intervention			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Nervous system disorders			
hypoxic brain damage, inauspicious prognosis			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Blood and lymphatic system disorders			
Leucopenia			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
incomplete retinal central vein occlusion right eye			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
ulcerous stomach with hemorrhagic oozing			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
unclear abdominal discomforts			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
wound healing disease			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
acute allograft Rejection Banff grade IA and IB			
subjects affected / exposed	2 / 67 (2.99%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

acute kidney failure with diuretic overdose				
subjects affected / exposed	1 / 67 (1.49%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
acute allograft Rejection Banff grade IIA and IIB				
subjects affected / exposed	2 / 67 (2.99%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
graft function worsening				
subjects affected / exposed	9 / 67 (13.43%)			
occurrences causally related to treatment / all	2 / 10			
deaths causally related to treatment / all	0 / 0			
hydronephrosis				
subjects affected / exposed	3 / 67 (4.48%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Incipient sepsis - probably source - urinary tract				
subjects affected / exposed	2 / 67 (2.99%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
increased creatinine				
subjects affected / exposed	3 / 67 (4.48%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Musculoskeletal and connective tissue disorders				
acute Chondrocalcinosis				
subjects affected / exposed	1 / 67 (1.49%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
contusion trauma				

subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
CMV colitis			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Fever			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Increasing viral load of polyomavirus in the blood			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
infected postoperative retroperitoneal haematoma			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
phlebitis with absces			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
pneumonia			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
urinary tract infection			
subjects affected / exposed	12 / 67 (17.91%)		
occurrences causally related to treatment / all	3 / 8		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			

Diabetic foot			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Gout			
subjects affected / exposed	1 / 67 (1.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Tacrolimus Group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	67 / 67 (100.00%)		
Injury, poisoning and procedural complications			
postoperative pain/surgery pain			
subjects affected / exposed	51 / 67 (76.12%)		
occurrences (all)	52		
Vascular disorders			
increased blood pressure/hypertension			
subjects affected / exposed	22 / 67 (32.84%)		
occurrences (all)	29		
Cardiac disorders			
edema (leg)			
subjects affected / exposed	22 / 67 (32.84%)		
occurrences (all)	25		
Nervous system disorders			
headache			
subjects affected / exposed	10 / 67 (14.93%)		
occurrences (all)	11		
Blood and lymphatic system disorders			
worsening anemia			
subjects affected / exposed	13 / 67 (19.40%)		
occurrences (all)	14		
Leukopenia			

subjects affected / exposed occurrences (all)	11 / 67 (16.42%) 12		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	11 / 67 (16.42%)		
occurrences (all)	14		
Vomitting			
subjects affected / exposed	12 / 67 (17.91%)		
occurrences (all)	15		
nausea			
subjects affected / exposed	10 / 67 (14.93%)		
occurrences (all)	14		
obstipation			
subjects affected / exposed	13 / 67 (19.40%)		
occurrences (all)	15		
Respiratory, thoracic and mediastinal disorders			
dyspnoe			
subjects affected / exposed	6 / 67 (8.96%)		
occurrences (all)	10		
Renal and urinary disorders			
delayed graft function			
subjects affected / exposed	13 / 67 (19.40%)		
occurrences (all)	13		
leukocyturia			
subjects affected / exposed	7 / 67 (10.45%)		
occurrences (all)	7		
increased creatinine			
subjects affected / exposed	11 / 67 (16.42%)		
occurrences (all)	16		
dysuria			
subjects affected / exposed	18 / 67 (26.87%)		
occurrences (all)	18		
Psychiatric disorders			
sleeping disorder			
subjects affected / exposed	11 / 67 (16.42%)		
occurrences (all)	13		

Infections and infestations			
	Additional description:	4 Subject with Bk-Virus;	4 Patients with CMV
BK-Virus,CMV			
subjects affected / exposed	7 / 67 (10.45%)		
occurrences (all)	7		
increased CRP			
subjects affected / exposed	11 / 67 (16.42%)		
occurrences (all)	12		
fever/ increased body temerature			
subjects affected / exposed	6 / 67 (8.96%)		
occurrences (all)	7		
Urinary Tract Infection			
subjects affected / exposed	17 / 67 (25.37%)		
occurrences (all)	25		
upper tract, Cough, Brochitis, Pneumonia			
subjects affected / exposed	13 / 67 (19.40%)		
occurrences (all)	15		
common cold			
subjects affected / exposed	8 / 67 (11.94%)		
occurrences (all)	13		
Metabolism and nutrition disorders			
Hypocalcemia			
subjects affected / exposed	8 / 67 (11.94%)		
occurrences (all)	8		
Hypouricemia			
subjects affected / exposed	12 / 67 (17.91%)		
occurrences (all)	12		
Hyperkalemia			
subjects affected / exposed	25 / 67 (37.31%)		
occurrences (all)	25		
Hyperglycemia			
subjects affected / exposed	16 / 67 (23.88%)		
occurrences (all)	16		
acidose			
subjects affected / exposed	20 / 67 (29.85%)		
occurrences (all)	21		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 October 2017	Change of the protocol; Further specification of an exclusion criterion, with respect to safety reasons

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/37525369>